Staidson (Beijing) BioPharmaceuticals Co., Ltd.
舒泰神
300204
Shenzhen Stock Exchange
Company Profile
Innovative research and development. Our mission is to "continue to innovate, provide safe and effective treatment drugs and make contribution to human health". We attach great importance to the continuous innovation of products and technologies. Staidson has been recognized as innovative pilot projects of Beijing High-tech Enterprises and Zhongguancun National Independent Innovation Demonstration Zone Enterprise, and the advanced scientific and technological innovation unit of Beijing Economic and Technological Development Zone. Advantage of product brand. The main product of our company, Su Tai Sheng, is the first drug to be certificated in China in the field of nerve growth factor candidates, and the first drug to finish phrase IV clinical experiments after getting the certificate to sale. In order to expand the clinical application of Su Tai Sheng, Staidson applied and received the clinical approval for the new indications of "diabetic foot" and "traumatic peripheral nerve injury" in 2016 respectively. As another internationally recognized leading product, freecol is the first-line candidate in the field of Ethylene glycol products, ranking the first in the market of bowel cleansing. Advantages in Corporate culture and human resources. We have a stable and cohesive team with rich management experience and many years of experience in biopharmaceutical industry, which has a common understanding and solid pursuit to develop, produce and sell "safe and effective therapeutic drugs".
Full description
Staidson is an innovative biopharmaceutical company focused on the research and development, manufacturing and marketing of innovative drugs. The company specializes in the research and development, manufacture and sale of therapeutic and innovative drugs, especially protein drugs, gene drugs and chemical drugs. The main therapeutic areas cover diseases of the nervous system, infectious diseases, gastrointestinal diseases and urological diseases as well as autoimmune diseases etc. The company's main products are innovative biological drug Su Tai Sheng (Mouse Nerve Growth Factor for Injection) and the national exclusive product Freecol (polyethylene glycol electrolytes powder (IV)). Details of main products are as follows: Since 1995, Staidson has started research and development of Su Tai Sheng, and was issued a new drug certificate and production certificate by China Food and Drug Administration (CFDA) in 2006. Su Tai Sheng is the first drug to be certificated in China in the field of nerve growth factor candidates, a State class new medicine with independent intellectual property rights, with an indication of "promoting nerve injury recovery, for the treatment of optic nerve injury." Su Tai Sheng was included in the "national basic medical insurance, industrial injury insurance and maternity insurance drugs directory" both in 2009 and 2017, with its market covers all over China. The new drug certificate and production certificate of Freecol was issued by China Food and Drug Administration (CFDA) in 2004. Freecol is used "for the treatment of functional constipation; for preoperative bowel cleansing preparation, colonoscopy and other pre-bowel cleansing preparations." Freecol was included in the "national basic medical insurance, industrial injury insurance and maternity insurance drugs directory" both in 2009 and 2017, with its market covers all over China except Tibet. Shu Wei Xin (trospium chloride capsule) is another new product with significant competitive advantage. In 2016, the Company completed the formulation and implementation of marketing strategy in the initial stage, and completed market access procedures in various provinces and cities. Shu Wei Xin is used "for the treatment of patients of over-activity of the bladder (OAB) with frequent urination, urgency, incontinence and other symptoms." Compared with the existing drugs for the treatment of OAB, Shu Wei Xin has good targeting ability, with no access to the central nervous system and minimal impact on the combination use of drugs, providing effective treatment drug for over 70million domestic patients. The company also has a wealth of research programs, including a number of State class new biological products and specialty chemicals with independent intellectual property rights. The abundant reserves of research programs and the constant attention and extension of innovative biopharmaceuticals lay a good foundation for the sustainable development of the Company in the future.